Clicky

Friday, November 20, 2026
All public companies · Official EDGAR

ORICOric Pharmaceuticals, Inc.

Nasdaq · CIK 0001796280
Filer categoryNon-accelerated filer
Entity typeoperating
SIC2834 Pharmaceutical Preparations
FY end1231
XBRL facts215

Identity from submissions API

NameOric Pharmaceuticals, Inc.
CIK0001796280
TickersORIC
ExchangesNasdaq
Entity typeoperating
CategoryNon-accelerated filer
SIC2834 Pharmaceutical Preparations
EIN471787157
LEI—
Fiscal year end1231
State of incorporationDE DE
Phone(650) 388-5600
Website—
Investor website—
Owner org03 Life Sciences
Flags—
Description—
Insider transactions (issuer)1
Insider transactions (owner)0

Former names

  • None listed.
Business address
240 E. GRAND AVE.
2ND FLOOR
SOUTH SAN FRANCISCO
CA
94080
CA
Mailing address
240 E. GRAND AVE.
2ND FLOOR
SOUTH SAN FRANCISCO
CA
94080
CA

EDGAR has no company-logo API. Website field is shown when the filer provided one.

Financialist coverage

SEC filings

428 filing rows loaded from submissions recent.

FiledFormDocumentItemsAccessionFile no.FilmActSizeXBRLiXBRL
2026-11-16 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000905148-26-004951 005-91490 261562269 34 39402
2026-11-16 10-Q 10-Q 0001193125-26-463577 001-39269 261561402 34 7583893 1 1
2026-11-16 8-K 8-K 2.02,9.01 0001193125-26-463506 001-39269 261560849 34 455102 1 1
2026-11-16 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000935836-26-000590 005-91490 261559321 34 15904
2026-11-16 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000080255-26-000706 005-91490 261556441 34 7864
2026-10-23 8-K 8-K 7.01,8.01,9.01 0001193125-26-429465 001-39269 261479932 34 20334273 1 1
2026-10-21 4 xslF345X06/form4-10212026_091012.xml 0001695028-26-000012 9043
2026-10-02 4 xslF345X06/form4-10022026_091044.xml 0001584759-26-000017 10842
2026-10-01 144 xsl144X01/primary_doc.xml 0001968582-26-001030 001-39269 261431668 33 8373
2026-10-01 144 xsl144X01/primary_doc.xml 0001968582-26-001029 001-39269 261431654 33 7729
2026-09-29 4 xslF345X06/form4-09292026_110919.xml 0001695028-26-000010 9044
2026-09-25 4 xslF345X06/form4-09252026_110926.xml 0001695028-26-000008 10107
2026-08-28 4 xslF345X06/form4-08282026_080834.xml 0001695028-26-000006 12569
2026-08-26 144 xsl144X01/primary_doc.xml 0001968582-26-000883 001-39269 261322936 33 7381
2026-08-03 10-Q 10-Q 0001193125-26-330631 001-39269 261233220 34 7047165 1 1
2026-08-03 8-K 8-K 2.02,9.01 0001193125-26-330568 001-39269 261232934 34 423978 1 1
2026-07-30 S-8 S-8 0001193125-26-326363 333-297837 261224544 33 212111 1 1
2026-07-30 8-K 8-K 5.02,9.01 0001193125-26-326309 001-39269 261224141 34 257207 1 1
2026-07-28 4 xslF345X06/form4-07282026_080709.xml 0001584759-26-000015 10385
2026-07-08 4 xslF345X06/form4-07082026_080727.xml 0001584759-26-000012 5841
2026-07-06 144 xsl144X01/primary_doc.xml 0001968582-26-000699 001-39269 261156274 33 5570
2026-07-06 144 xsl144X01/primary_doc.xml 0001968582-26-000698 001-39269 261156268 33 4928
2026-06-22 8-K 8-K 5.02,5.07,9.01 0001193125-26-277511 001-39269 261107015 34 447786 1 1
2026-05-15 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000905148-26-002430 005-91490 26990047 34 39155
2026-05-15 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001738048-26-000058 005-91490 26988667 34 17954
2026-05-15 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000919574-26-003469 005-91490 26987866 34 11215
2026-05-15 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0000080255-26-000420 005-91490 26983452 34 7653
2026-05-12 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000078003-26-000067 005-91490 26969714 34 8948
2026-05-04 10-Q 10-Q 0001193125-26-204047 001-39269 26937947 34 6473010 1 1
2026-05-04 8-K 8-K 2.02,9.01 0001193125-26-203993 001-39269 26937662 34 381155 1 1
2026-04-28 ARS ARS 0001193125-26-186947 001-39269 26907676 34 2466619
2026-04-28 DEFA14A DEFA14A 0001193125-26-186921 001-39269 26907550 34 536224
2026-04-28 DEF 14A DEF 14A 0001193125-26-186911 001-39269 26907507 34 3169296 1 1
2026-03-31 8-K 8-K 8.01,9.01 0001193125-26-134618 001-39269 26822107 34 22563066 1 1
2026-02-26 4 xslF345X05/form4-02262026_090218.xml 0001695028-26-000004 8908
2026-02-24 144 xsl144X01/primary_doc.xml 0001968582-26-000149 001-39269 26671604 33 4395
2026-02-23 8-K 8-K 8.01,9.01 0001193125-26-064291 001-39269 26666284 34 188353 1 1
2026-02-23 424B5 424B5 0001193125-26-064275 333-277829 26666233 33 475009 1 1
2026-02-23 S-8 S-8 0001193125-26-064243 333-293661 26666133 33 212134 1 1
2026-02-23 10-K 10-K 0001193125-26-064005 001-39269 26665356 34 20705343 1 1
2026-02-23 8-K 8-K 2.02,9.01 0001193125-26-063974 001-39269 26665242 34 410012 1 1
2026-02-17 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001738048-26-000026 005-91490 26644149 34 17823
2026-01-21 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0002012383-26-000702 005-91490 26545869 34 10902
2026-01-20 4 xslF345X05/form4-01212026_120124.xml 0001584759-26-000006 7021
2026-01-16 144 xsl144X01/primary_doc.xml 0001968582-26-000038 001-39269 26540213 33 4562
2026-01-16 144 xsl144X01/primary_doc.xml 0001968582-26-000036 001-39269 26540071 33 4449
2026-01-06 4 xslF345X05/form4-01062026_090103.xml 0001647664-26-000002 5422
2026-01-06 4 xslF345X05/form4-01062026_090157.xml 0001536368-26-000002 5419
2026-01-06 4 xslF345X05/form4-01062026_090105.xml 0001533451-26-000002 5426
2026-01-06 4 xslF345X05/form4-01062026_090104.xml 0001584759-26-000003 5384
2026-01-06 4 xslF345X05/form4-01062026_090138.xml 0001574591-26-000002 5406
2026-01-06 4 xslF345X05/form4-01062026_090131.xml 0001695028-26-000002 7963
2026-01-06 4 xslF345X05/form4-01062026_090111.xml 0001586894-26-000002 7964
2026-01-06 4 xslF345X05/form4-01062026_090105.xml 0001608936-26-000002 7935
2025-12-17 4 xslF345X05/form4-12182025_121256.xml 0001586894-25-000005 14078
2025-12-17 4 xslF345X05/form4-12182025_121249.xml 0001695028-25-000008 14061
2025-12-17 4 xslF345X05/form4-12182025_121249.xml 0001608936-25-000014 13851
2025-12-16 144 xsl144X01/primary_doc.xml 0001695028-25-000007 001-39269 251577096 33 5060
2025-12-16 144 xsl144X01/primary_doc.xml 0001586894-25-000004 001-39269 251577088 33 4413
2025-12-16 144 xsl144X01/primary_doc.xml 0001608936-25-000013 001-39269 251577082 33 7024
2025-12-09 4 xslF345X05/form4-12092025_101258.xml 0001536368-25-000006 7033
2025-12-08 8-K 8-K 8.01,9.01 0001193125-25-310472 001-39269 251554518 34 21886546 1 1
2025-12-05 4 xslF345X05/form4-12052025_101227.xml 0001536368-25-000004 7154
2025-11-17 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001193125-25-284976 005-91490 251492536 34 15000
2025-11-13 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000902664-25-004920 005-91490 251480224 34 10699
2025-11-13 8-K 8-K 7.01,9.01 0001193125-25-280247 001-39269 251478931 34 1670980 1 1
2025-11-13 10-Q 10-Q 0001193125-25-280234 001-39269 251478851 34 7055211 1 1
2025-11-13 8-K 8-K 2.02,9.01 0001193125-25-280196 001-39269 251478681 34 614803 1 1
2025-10-08 4 xslF345X05/form4-10082025_091013.xml 0001695028-25-000004 8908
2025-10-08 4 xslF345X05/form4-10082025_091029.xml 0001608936-25-000010 5690
2025-10-06 144 xsl144X01/primary_doc.xml 0001968582-25-000980 001-39269 251377097 33 4545
2025-10-03 4 xslF345X05/form4-10032025_111055.xml 0001584759-25-000004 13443
2025-10-02 4 xslF345X05/form4-10022025_111028.xml 0001608936-25-000008 7684
2025-09-24 4 xslF345X05/form4-09242025_080916.xml 0001608936-25-000006 5874
2025-09-22 144 xsl144X01/primary_doc.xml 0001968582-25-000950 001-39269 251330479 33 4557
2025-08-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000905148-25-002996 005-91490 251221305 34 42436
2025-08-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001415889-25-021933 005-91490 251220530 34 14877
2025-08-14 SCHEDULE 13D/A xslSCHEDULE_13D_X01/primary_doc.xml 0000950170-25-108850 005-91490 251218709 34 393052
2025-08-12 10-Q 10-Q 0000950170-25-107359 001-39269 251207027 34 6860047 1 1
2025-08-12 8-K 8-K 2.02,2.05,9.01 0000950170-25-107313 001-39269 251206780 34 624424 1 1
2025-08-05 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0000935836-25-000480 005-91490 251186611 34 15740
2025-07-17 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0002052113-25-003103 005-91490 251132276 34 10887
2025-07-02 4 xslF345X05/form4-07022025_080708.xml 0001415889-25-019000 5314
2025-06-24 4 xslF345X05/form4-06242025_100608.xml 0001415889-25-018128 8330
2025-06-24 424B3 424B3 0001193125-25-145721 333-287949 251068989 33 200408
2025-06-23 4 xslF345X05/form4-06242025_120613.xml 0001415889-25-018014 6554
2025-06-20 EFFECT xslEFFECTX01/primary_doc.xml ,, 9999999995-25-001981 333-287949 251062836 33 1780
2025-06-17 CORRESP filename1.htm 0001193125-25-142046 8255
2025-06-16 UPLOAD filename1.pdf 0000000000-25-006298 333-287949 40152
2025-06-13 4 xslF345X05/form4-06132025_110620.xml 0001415889-25-017325 4871
2025-06-13 8-K 8-K 5.07 0001193125-25-140725 001-39269 251046463 34 146724 1 1
2025-06-11 4 xslF345X05/form4-06112025_100647.xml 0001415889-25-016739 8086
2025-06-11 S-3 S-3 0001193125-25-139139 333-287949 251039957 33 303389
2025-06-09 4 xslF345X05/form4-06102025_120617.xml 0001415889-25-016386 6819
2025-06-06 144 xsl144X01/primary_doc.xml 0001968582-25-000467 001-39269 251030892 33 4524
2025-06-06 D xslFormDX01/primary_doc.xml 06b 0001796280-25-000001 021-548268 251029664 33 12206
2025-06-05 SCHEDULE 13D xslSCHEDULE_13D_X01/primary_doc.xml 0000950170-25-082520 005-91490 251028164 34 462348
2025-06-04 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0000902664-25-002631 005-91490 251023600 34 17501
2025-05-30 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001415889-25-015010 005-91490 251011601 34 34964
2025-05-28 8-K 8-K 1.01,3.02,7.01,8.01,9.01 0001193125-25-129531 001-39269 25996005 34 555373 1 1
2025-05-15 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001415889-25-013266 005-91490 25956183 34 24672
2025-05-15 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000905148-25-001761 005-91490 25954331 34 38133
2025-05-15 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001415889-25-012988 005-91490 25949393 34 57736
2025-05-05 10-Q 10-Q 0000950170-25-063564 001-39269 25913282 34 6148724 1 1
2025-05-05 8-K 8-K 2.02,9.01 0000950170-25-063540 001-39269 25913017 34 567752 1 1
2025-04-23 ARS ARS 0001193125-25-091384 001-39269 25861700 34 52396431
2025-04-23 DEFA14A DEFA14A 0001193125-25-091370 001-39269 25861545 34 188130
2025-04-23 DEF 14A DEF 14A 0001193125-25-091359 001-39269 25861471 34 1713544 1 1
2025-03-20 S-8 S-8 0001193125-25-059251 333-285959 25756821 33 100541
2025-03-14 8-K 8-K 5.02,9.01 0001193125-25-054784 001-39269 25739864 34 431529 1 1
2025-03-04 4 xslF345X05/form4-03042025_100357.xml 0001415889-25-006616 10755
2025-02-25 8-K 8-K 8.01,9.01 0001193125-25-035203 001-39269 25663971 34 176935 1 1
2025-02-18 10-K 10-K 0000950170-25-022273 001-39269 25635180 34 19756808 1 1
2025-02-18 8-K 8-K 2.02,9.01 0000950170-25-022219 001-39269 25634961 34 605302 1 1
2025-02-12 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000315066-25-000894 005-91490 25612576 34 11491
2025-01-13 8-K 8-K 7.01,9.01 0001193125-25-005028 001-39269 25524965 34 17724016 1 1
2025-01-06 4 xslF345X05/form4-01062025_090153.xml 0001415889-25-000795 5429
2025-01-06 4 xslF345X05/form4-01062025_090135.xml 0001415889-25-000792 5428
2025-01-06 4 xslF345X05/form4-01062025_090139.xml 0001415889-25-000788 5433
2025-01-06 4 xslF345X05/form4-01062025_090141.xml 0001415889-25-000785 5398
2025-01-06 4 xslF345X05/form4-01062025_090133.xml 0001415889-25-000782 5413
2025-01-03 4 xslF345X05/form4-01032025_100144.xml 0001415889-25-000602 7971
2025-01-03 4 xslF345X05/form4-01032025_100150.xml 0001415889-25-000601 7970
2025-01-03 4 xslF345X05/form4-01032025_100156.xml 0001415889-25-000600 7942
2024-12-17 4 xslF345X05/form4-12172024_101232.xml 0001415889-24-029634 14077
2024-12-17 4 xslF345X05/form4-12172024_101230.xml 0001415889-24-029633 14076
2024-12-17 4 xslF345X05/form4-12172024_101258.xml 0001415889-24-029631 14053
2024-12-16 144 xsl144X01/primary_doc.xml 0001796280-24-000007 001-39269 241553474 33 4419
2024-12-16 144 xsl144X01/primary_doc.xml 0001796280-24-000006 001-39269 241553473 33 4456
2024-12-16 144 xsl144X01/primary_doc.xml 0001796280-24-000005 001-39269 241553464 33 4416
2024-11-14 SC 13G/A oric13ga5.htm 0000935836-24-000716 005-91490 241464819 34 48236
2024-11-14 SC 13G/A SC 13G/A 0001104659-24-119315 005-91490 241464757 34 117357
2024-11-14 SC 13G/A SC 13G/A 0001193125-24-258788 005-91490 241464275 34 75802
2024-11-13 SC 13G/A ORIC PHARMACEUTICALS, INC. 0000902664-24-006454 005-91490 241451592 34 62130
2024-11-12 10-Q 10-Q 0000950170-24-125471 001-39269 241448565 34 6466976 1 1
2024-11-12 8-K 8-K 2.02,9.01 0000950170-24-125386 001-39269 241448162 34 416515 1 1
2024-11-12 SC 13G/A filing.txt 0000315066-24-002779 005-91490 241444875 34 8119
2024-11-08 SC 13G us68622p1093_110824.txt 0002012383-24-003654 005-91490 241439778 34 13886
2024-10-22 SC 13G us68622p1093_102224.txt 0002012383-24-001558 005-91490 241387308 34 13874
2024-08-12 10-Q 10-Q 0000950170-24-095467 001-39269 241197075 34 6347948 1 1
2024-08-12 8-K 8-K 2.02,9.01 0000950170-24-095419 001-39269 241196849 34 428786 1 1
2024-06-14 4 xslF345X05/form4-06142024_080646.xml 0001415889-24-016916 5564
2024-06-14 4 xslF345X05/form4-06142024_080645.xml 0001415889-24-016913 5563
2024-06-14 4 xslF345X05/form4-06142024_080617.xml 0001415889-24-016909 5568
2024-06-14 4 xslF345X05/form4-06142024_080637.xml 0001415889-24-016906 5548
2024-06-14 4 xslF345X05/form4-06142024_080630.xml 0001415889-24-016903 5533
2024-06-14 8-K 8-K 5.07 0001193125-24-161593 001-39269 241044730 34 155128 1 1
2024-06-04 4 xslF345X05/form4-06042024_100642.xml 0001415889-24-015475 7168
2024-05-06 10-Q 10-Q 0000950170-24-053582 001-39269 24917825 34 5827232 1 1
2024-05-06 8-K 8-K 2.02,9.01 0000950170-24-053551 001-39269 24917574 34 381724 1 1
2024-04-24 ARS ARS 0001193125-24-110119 001-39269 24870773 34 3088330
2024-04-24 DEFA14A DEFA14A 0001193125-24-110091 001-39269 24870673 34 425541
2024-04-24 DEF 14A DEF 14A 0001193125-24-110069 001-39269 24870584 34 509195
2024-03-29 S-8 S-8 0001193125-24-082131 333-278394 24804586 33 98297
2024-03-29 8-K 8-K 5.02,9.01 0001193125-24-082077 001-39269 24804268 34 267529 1 1
2024-03-11 S-3ASR S-3ASR 0001193125-24-064987 333-277829 24739252 33 868351
2024-03-11 10-K 10-K 0000950170-24-029298 001-39269 24738307 34 13755857 1 1
2024-03-11 8-K 8-K 2.02,9.01 0000950170-24-029239 001-39269 24738071 34 414629 1 1
2024-03-11 SC 13G/A filing.txt 0000315066-24-001676 005-91490 24736616 34 8255
2024-03-08 4 xslF345X05/form4-03082024_090337.xml 0001415889-24-007345 5289
2024-03-06 144 xsl144X01/primary_doc.xml 0001968582-24-000194 001-39269 24726282 33 5757
2024-02-14 SC 13G/A oric13ga4.htm 0000935836-24-000217 005-91490 24641193 34 48598
2024-02-13 SC 13G/A oric13ga2024.htm 0000935836-24-000150 005-91490 24630849 34 42397
2024-02-13 SC 13G/A SC 13G/A 0001193125-24-033022 005-91490 24622927 34 109041
2024-02-09 SC 13G/A filing.txt 0000315066-24-001351 005-91490 24611929 34 8322
2024-02-08 4 xslF345X05/form4-02092024_010219.xml 0001415889-24-003114 7239
2024-02-07 SC 13G/A us68622p1093_020724.txt 0001086364-24-006812 005-91490 24605691 34 12580
2024-02-06 SC 13G/A ORIC_SC13GA.htm 0001273087-24-000038 005-91490 24600395 34 81630
2024-02-06 144 xsl144X01/primary_doc.xml 0001968582-24-000089 001-39269 24600205 33 4499
2024-02-02 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2024-02-02 16:00:00 9999999995-24-000311 333-276719 24593783 33 1786
2024-02-01 SC 13G SC 13G 0001104659-24-009469 005-91490 24587128 34 184186
2024-01-31 CORRESP filename1.htm 0001193125-24-021092 7472
2024-01-31 UPLOAD filename1.pdf 0000000000-24-001224 333-276719 40422
2024-01-30 SC 13G SC 13G 0001140361-24-004573 005-91490 24578613 34 357216
2024-01-30 D xslFormDX01/primary_doc.xml 06b 0001796280-24-000001 021-503858 24576739 33 12104
2024-01-29 SC 13G us68622p1093_012924.txt 0001086364-24-005597 005-91490 24574924 34 13449
2024-01-26 S-3 S-3 0001193125-24-016819 333-276719 24568722 33 287636
2024-01-25 SC 13G SC 13G 0001193125-24-015197 005-91490 24560838 34 330590
2024-01-22 8-K 8-K 1.01,3.02,7.01,9.01 0001193125-24-011747 001-39269 24547222 34 379620 1 1
2024-01-09 8-K 8-K 2.02,7.01,9.01 0001193125-24-004909 001-39269 24521898 34 22069194 1 1
2024-01-03 4 FORM 4 SUBMISSION 0001209191-24-000368 8074
2024-01-03 4 FORM 4 SUBMISSION 0001209191-24-000364 8073
2024-01-03 4 FORM 4 SUBMISSION 0001209191-24-000361 8043
2023-12-28 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2023-12-28 16:00:00 9999999995-23-003785 333-276077 231524194 33 1787
2023-12-26 CORRESP filename1.htm 0001193125-23-303005 9526
2023-12-22 UPLOAD filename1.pdf 0000000000-23-014043 40323
2023-12-19 4 FORM 4 SUBMISSION 0001209191-23-059266 12075
2023-12-19 4 FORM 4 SUBMISSION 0001209191-23-059264 12074
2023-12-19 4 FORM 4 SUBMISSION 0001209191-23-059263 12036
2023-12-15 S-3 S-3 0001193125-23-296691 333-276077 231490849 33 296696
2023-12-11 8-K 8-K 8.01,9.01 0001193125-23-292551 001-39269 231478172 34 174437 1 1
2023-11-06 10-Q 10-Q 0000950170-23-059415 001-39269 231380240 34 7608717 1 1
2023-11-06 8-K 8-K 2.02,9.01 0000950170-23-059392 001-39269 231380062 34 477909 1 1
2023-10-23 8-K 8-K 8.01,9.01 0001193125-23-260795 001-39269 231340078 34 186089 1 1
2023-08-10 10-Q 10-Q 0000950170-23-041362 001-39269 231159814 34 8077427 1 1
2023-08-10 8-K 8-K 2.02,9.01 0000950170-23-041326 001-39269 231159472 34 457786 1 1
2023-07-11 4 FORM 4 SUBMISSION 0001209191-23-042054 7256
2023-07-07 4 FORM 4 SUBMISSION 0001209191-23-041805 5258
2023-07-07 SC 13G SC 13G 0001104659-23-079126 005-91490 231076942 34 109763
2023-07-05 144 xsl144X01/primary_doc.xml 0001968582-23-000305 001-39269 231068864 33 5047
2023-07-05 D xslFormDX01/primary_doc.xml 06b 0001796280-23-000001 021-485949 231068327 33 12118
2023-06-28 4 FORM 4 SUBMISSION 0001209191-23-040090 5439
2023-06-27 8-K 8-K 1.01,3.02,7.01,9.01 0001193125-23-175501 001-39269 231043918 34 492216 1 1
2023-06-26 144 xsl144X01/primary_doc.xml 0001968582-23-000278 001-39269 231043586 33 4419
2023-06-15 4 FORM 4 SUBMISSION 0001209191-23-037398 5490
2023-06-15 4 FORM 4 SUBMISSION 0001209191-23-037396 5489
2023-06-15 4 FORM 4 SUBMISSION 0001209191-23-037395 5494
2023-06-15 4 FORM 4 SUBMISSION 0001209191-23-037394 5459
2023-06-15 4 FORM 4 SUBMISSION 0001209191-23-037393 5474
2023-06-15 8-K 8-K 5.07 0001193125-23-167893 001-39269 231017383 34 154489 1 1
2023-06-12 SC 13G SC 13G 0001193125-23-164656 005-91490 231006865 34 125365
2023-05-08 10-Q 10-Q 0000950170-23-018839 001-39269 23898067 34 7445007 1 1
2023-05-08 8-K 8-K 2.02,9.01 0000950170-23-018807 001-39269 23897835 34 400203 1 1
2023-04-26 ARS ARS 0001193125-23-118525 001-39269 23849836 34 1802282
2023-04-26 DEFA14A DEFA14A 0001193125-23-118512 001-39269 23849784 34 288120
2023-04-26 DEF 14A DEF 14A 0001193125-23-118496 001-39269 23849708 34 678981
2023-03-24 8-K 8-K 5.03,9.01 0001193125-23-079104 001-39269 23759901 34 393689 1 1
2023-03-16 S-8 S-8 0001193125-23-072705 333-270619 23739590 33 94386
2023-03-16 10-K 10-K 0000950170-23-008483 001-39269 23739126 34 13865481 1 1
2023-03-16 8-K 8-K 2.02,9.01 0000950170-23-008457 001-39269 23738881 34 479703 1 1
2023-02-17 4/A FORM 4/A SUBMISSION 0001209191-23-010616 5171
2023-02-17 4/A FORM 4/A SUBMISSION 0001209191-23-010611 5171
2023-02-17 4/A FORM 4/A SUBMISSION 0001209191-23-010607 5085
2023-02-13 SC 13G/A oric13ga.htm 0000935836-23-000129 005-91490 23615403 34 42195
2023-02-10 SC 13G/A oric13ga2022.htm 0000935836-23-000103 005-91490 23610335 34 47368
2023-02-09 SC 13G/A filing.txt 0000315066-23-001947 005-91490 23604825 34 8155
2023-02-06 SC 13G/A oricpharma13ga1_123122.htm 0001040188-23-000047 005-91490 23588897 34 43857
2023-02-02 4 FORM 4 SUBMISSION 0001209191-23-006198 7961
2023-02-02 4 FORM 4 SUBMISSION 0001209191-23-006195 7960
2023-02-02 4 FORM 4 SUBMISSION 0001209191-23-006191 7930
2023-01-20 SC 13G ORIC_SC13G.htm 0001273087-23-000043 005-91490 23541067 34 81560
2023-01-09 8-K 8-K 2.02,7.01,9.01 0001193125-23-004194 001-39269 23516712 34 182943 1 1
2022-12-29 SC 13G SC 13G ORIC PHARMACEUTICALS 0000078003-22-000112 005-91490 221499247 34 34873
2022-12-29 3 PRIMARY DOCUMENT 0000078003-22-000110 3770
2022-12-27 SC 13D/A AMENDMENT NO. 4 0000947871-22-001255 005-91490 221490746 34 113007
2022-12-21 8-K 8-K 8.01,9.01 0001193125-22-310169 001-39269 221479190 34 346666 1 1
2022-12-21 424B5 424B5 0001193125-22-310167 333-255833 221479181 33 548963
2022-12-16 4 FORM 4 SUBMISSION 0001209191-22-061756 9205
2022-12-16 4 FORM 4 SUBMISSION 0001209191-22-061755 9207
2022-12-16 4 FORM 4 SUBMISSION 0001209191-22-061754 9181
2022-11-07 10-Q 10-Q 0000950170-22-022631 001-39269 221365760 34 8285534 1 1
2022-11-07 8-K 8-K 2.02,9.01 0000950170-22-022600 001-39269 221365513 34 477406 1 1
2022-08-11 10-Q 10-Q 0000950170-22-016894 001-39269 221156188 34 7647556 1 1
2022-08-11 8-K 8-K 2.02,9.01 0000950170-22-016870 001-39269 221155831 34 451743 1 1
2022-07-21 4 FORM 4 SUBMISSION 0001209191-22-042843 17537
2022-07-21 4 FORM 4 SUBMISSION 0001209191-22-042842 22105
2022-07-21 4 FORM 4 SUBMISSION 0001209191-22-042841 17511
2022-07-21 SC TO-I/A SC TO-I/A 0001193125-22-199146 005-91490 221097095 34 18476
2022-07-08 SC 13G us68622p1093_070822.txt 0000834237-22-010293 005-91490 221075055 34 12215
2022-06-21 SC TO-I SC TO-I 0001193125-22-177627 005-91490 221028189 34 10773442
2022-06-21 8-K 8-K 5.07 0001193125-22-176987 001-39269 221025881 34 154264 1 1
2022-06-17 4 FORM 4 SUBMISSION 0001209191-22-038203 5587
2022-06-17 4 FORM 4 SUBMISSION 0001209191-22-038201 5586
2022-06-17 4 FORM 4 SUBMISSION 0001209191-22-038200 5556
2022-06-17 4 FORM 4 SUBMISSION 0001209191-22-038199 5591
2022-06-17 4 FORM 4 SUBMISSION 0001209191-22-038197 5587
2022-05-13 4 FORM 4 SUBMISSION 0001209191-22-028963 8979
2022-05-09 10-Q 10-Q 0000950170-22-008512 001-39269 22905352 34 8326251 1 1
2022-05-09 8-K 8-K 2.02,9.01 0000950170-22-008492 001-39269 22905030 34 393263 1 1
2022-04-27 EFFECT xslEFFECTX01/primary_doc.xml POS AM,0001193125-22-081609,2022-04-27 9999999995-22-001112 333-255833 22861930 33 1750
2022-04-27 DEFA14A DEFA14A 0001193125-22-123601 001-39269 22859568 34 43232
2022-04-27 DEF 14A DEF 14A 0001193125-22-123589 001-39269 22859515 34 387546
2022-03-31 4 FORM 4 SUBMISSION 0001209191-22-021875 5064
2022-03-25 4 FORM 4 SUBMISSION 0001209191-22-021153 8980
2022-03-22 S-8 S-8 0001193125-22-081616 333-263763 22759629 33 98724
2022-03-22 POS AM POS AM 0001193125-22-081609 333-255833 22759585 33 543100
2022-03-21 8-K 8-K 7.01,9.01 0001193125-22-080683 001-39269 22756355 34 7780983 1 1
2022-03-21 10-K 10-K 0000950170-22-004239 001-39269 22756219 34 14147844 1 1
2022-03-21 8-K 8-K 2.02,9.01 0001193125-22-080529 001-39269 22755794 34 237623 1 1
2022-03-21 POSASR POSASR 0001193125-22-080510 333-255833 22755739 33 489316
2022-03-04 8-K 8-K 5.02,9.01 0001193125-22-066051 001-39269 22713976 34 431783 1 1
2022-02-14 SC 13G/A oricpharmaceuticals13ga.htm 0000935836-22-000162 005-91490 22630106 34 47405
2022-02-11 SC 13G/A SC 13G/A 0001193125-22-037274 005-91490 22622203 34 79075
2022-02-09 SC 13G/A filing.txt 0000315066-22-001318 005-91490 22604789 34 8500
2022-02-03 SC 13G/A us68622p1093_020322.txt 0000834237-22-006284 005-91490 22588994 34 13392
2022-02-02 4 FORM 4 SUBMISSION 0001209191-22-006339 7961
2022-02-02 4 FORM 4 SUBMISSION 0001209191-22-006337 7960
2022-02-02 4 FORM 4 SUBMISSION 0001209191-22-006336 7930
2022-02-02 SC 13G oricpharma13g_123121.htm 0001040188-22-000052 005-91490 22583478 34 43847
2022-01-10 8-K 8-K 2.02,8.01,9.01 0001193125-22-005116 001-39269 22519776 34 180332 1 1
2021-11-16 4 FORM 4 SUBMISSION 0000899243-21-044836 27142
2021-11-10 4 FORM 4 SUBMISSION 0001209191-21-063926 5343
2021-11-10 3 FORM 3 SUBMISSION 0001209191-21-063925 5450
2021-11-10 8-K 8-K 5.02,9.01 0001193125-21-326034 001-39269 211396975 34 177861 1 1
2021-11-08 10-Q 10-Q 0000950170-21-003477 001-39269 211388296 34 7834440 1 1
2021-11-08 8-K 8-K 2.02,9.01 0000950170-21-003470 001-39269 211388151 34 469044 1 1
2021-10-07 8-K 8-K 8.01,9.01 0001193125-21-294159 001-39269 211312454 34 196407 1 1
2021-09-16 4 FORM 4 SUBMISSION 0001209191-21-056461 8188
2021-09-16 4 FORM 4 SUBMISSION 0001209191-21-056460 7203
2021-09-14 4 FORM 4 SUBMISSION 0001209191-21-055871 8188
2021-09-14 4 FORM 4 SUBMISSION 0001209191-21-055866 7205
2021-09-09 4 FORM 4 SUBMISSION 0001209191-21-055295 6031
2021-09-09 4 FORM 4 SUBMISSION 0001209191-21-055291 7202
2021-08-18 8-K 8-K 8.01 0001193125-21-249636 001-39269 211184951 34 147503 1 1
2021-08-16 4 FORM 4 SUBMISSION 0001209191-21-051657 5308
2021-08-16 3 FORM 3 SUBMISSION 0001209191-21-051654 5428
2021-08-16 8-K 8-K 1.01,5.02,9.01 0001193125-21-247855 001-39269 211179135 34 487361 1 1
2021-08-12 SC 13D/A AMENDMENT NO. 3 0000947871-21-000903 005-91490 211167806 34 115515
2021-08-10 10-Q 10-Q 0000950170-21-001185 001-39269 211160233 34 6433157 1 1
2021-08-10 8-K 8-K 2.02,9.01 0000950170-21-001179 001-39269 211160094 34 426907 1 1
2021-07-12 8-K 8-K 8.01 0001193125-21-213171 001-39269 211086096 34 155499 1 1
2021-07-08 8-K 8-K 8.01,9.01 0001193125-21-210224 001-39269 211078899 34 174138 1 1
2021-06-21 8-K 8-K 5.07,8.01,9.01 0001193125-21-195039 001-39269 211030535 34 210699 1 1
2021-06-17 4 FORM 4 SUBMISSION 0001209191-21-041747 7927
2021-06-17 4 FORM 4 SUBMISSION 0001209191-21-041745 7978
2021-06-17 4 FORM 4 SUBMISSION 0001209191-21-041743 7952
2021-06-17 4 FORM 4 SUBMISSION 0001209191-21-041741 7940
2021-06-17 4 FORM 4 SUBMISSION 0001209191-21-041738 7969
2021-05-28 4 FORM 4 SUBMISSION 0001209191-21-036686 5200
2021-05-24 4 FORM 4 SUBMISSION 0001209191-21-035525 9910
2021-05-24 4 FORM 4 SUBMISSION 0001209191-21-035524 8717
2021-05-24 4 FORM 4 SUBMISSION 0001209191-21-035523 8764
2021-05-18 4 FORM 4 SUBMISSION 0001209191-21-033817 13426
2021-05-18 4 FORM 4 SUBMISSION 0001209191-21-033815 12228
2021-05-18 4 FORM 4 SUBMISSION 0001209191-21-033813 13812
2021-05-13 4 FORM 4 SUBMISSION 0001209191-21-032510 5594
2021-05-13 4 FORM 4 SUBMISSION 0001209191-21-032509 8716
2021-05-13 4 FORM 4 SUBMISSION 0001209191-21-032508 9198
2021-05-06 8-K 8-K 1.01,9.01 0001193125-21-153455 001-39269 21898899 34 251460
2021-05-06 424B5 424B5 0001193125-21-153432 333-255833 21898785 33 336496
2021-05-06 S-3ASR S-3ASR 0001193125-21-153360 333-255833 21898412 33 596952
2021-05-06 10-Q 10-Q 0001564590-21-024997 001-39269 21898053 34 6069308 1 1
2021-05-06 8-K 8-K 2.02,9.01 0001564590-21-024966 001-39269 21897831 34 199930
2021-04-30 4 FORM 4 SUBMISSION 0001209191-21-029379 7319
2021-04-30 4 FORM 4 SUBMISSION 0001209191-21-029378 6285
2021-04-30 4 FORM 4 SUBMISSION 0001209191-21-029375 7200
2021-04-26 DEFA14A DEFA14A 0001193125-21-130240 001-39269 21851463 34 51055
2021-04-26 DEF 14A DEF 14A 0001193125-21-130074 001-39269 21851427 34 390613
2021-04-05 4 FORM 4 SUBMISSION 0001209191-21-025495 4724
2021-04-05 4 FORM 4 SUBMISSION 0001209191-21-025493 5594
2021-04-05 4 FORM 4 SUBMISSION 0001209191-21-025492 5203
2021-03-31 4 xslF345X03/ownership.xml 0000947871-21-000400 8343
2021-03-31 4 xslF345X03/ownership.xml 0000947871-21-000399 10385
2021-03-26 4 xslF345X03/ownership.xml 0000947871-21-000396 12304
2021-03-26 4 xslF345X03/ownership.xml 0000947871-21-000395 10262
2021-03-23 4 xslF345X03/ownership.xml 0000947871-21-000361 10071
2021-03-23 4 xslF345X03/ownership.xml 0000947871-21-000360 12113
2021-03-23 S-8 S-8 0001193125-21-091284 333-254626 21765390 33 71434
2021-03-23 10-K 10-K 0001564590-21-014865 001-39269 21765027 34 11657066 1 1
2021-03-23 8-K ORIC_Q4 2020 EARNING RELEASE 2.02,9.01 0001564590-21-014852 001-39269 21764906 34 295557
2021-03-22 SC 13D/A AMENDMENT NO. 2 0000947871-21-000353 005-91490 21759330 34 128481
2021-03-18 4 xslF345X03/ownership.xml 0000947871-21-000349 12298
2021-03-18 4 xslF345X03/ownership.xml 0000947871-21-000348 10256
2021-03-15 4 xslF345X03/ownership.xml 0000947871-21-000334 12485
2021-03-15 4 xslF345X03/ownership.xml 0000947871-21-000333 10257
2021-02-16 SC 13G/A oric13ga.htm 0000935836-21-000155 005-91490 21634758 34 46920
2021-02-16 SC 13G SC 13G 0001193125-21-042022 005-91490 21630688 34 93271
2021-02-08 SC 13G/A filing.txt 0000315066-21-001170 005-91490 21599711 34 8462
2021-02-02 4 FORM 4 SUBMISSION 0001209191-21-006964 5445
2021-02-02 4 FORM 4 SUBMISSION 0001209191-21-006963 5464
2021-02-02 4 FORM 4 SUBMISSION 0001209191-21-006962 5436
2021-02-02 SC 13G us68622p1093_020221.txt 0000834237-21-006936 005-91490 21580678 34 13296
2021-01-11 8-K 8-K 2.02,7.01,9.01 0001193125-21-005732 001-39269 21519046 34 21576516
2020-11-18 SC 13D/A AMENDMENT NO. 1 0000947871-20-000893 005-91490 201324430 34 115074
2020-11-13 424B4 424B4 0001193125-20-293217 333-250001 201312640 33 7660864
2020-11-12 S-1MEF S-1MEF 0001193125-20-292166 333-250053 201309039 33 58776
2020-11-12 EFFECT xslEFFECTX01/primary_doc.xml S-1,,2020-11-12 16:00:00 9999999995-20-003167 333-250001 201309004 33 1738
2020-11-10 CORRESP filename1.htm 0001193125-20-290268 8901
2020-11-10 CORRESP filename1.htm 0001193125-20-290260 7410
2020-11-10 S-1 S-1 0001193125-20-290157 333-250001 201301273 33 12763527 1
2020-11-05 10-Q 10Q 0001564590-20-051363 001-39269 201290901 34 7950644 1 1
2020-11-05 8-K 8-K 2.02,9.01 0001564590-20-051336 001-39269 201290722 34 297192
2020-11-05 4 OWNERSHIP DOCUMENT 0001104659-20-121613 11407
2020-11-05 SC 13G/A SC 13G/A 0001104659-20-121611 005-91490 201288975 34 93484
2020-10-19 8-K 8-K 8.01,9.01 0001564590-20-046772 001-39269 201246289 34 81349
2020-08-05 10-Q 10-Q 0001564590-20-036836 001-39269 201077621 34 6688460 1 1
2020-08-05 8-K 8-K 2.02,3.02,7.01,9.01 0001564590-20-036825 001-39269 201077489 34 307452
2020-07-28 UPLOAD filename1.pdf 0000000000-20-006880 40483
2020-07-20 DRS filename1.htm 0000950123-20-007048 377-03309 201036759 33 6855322
2020-06-10 4 FORM 4 SUBMISSION 0001209191-20-035596 5301
2020-06-10 3 FORM 3 SUBMISSION 0001209191-20-035595 6053
2020-06-10 8-K 8-K 5.02,9.01 0001564590-20-028816 001-39269 20953435 34 50333
2020-05-20 10-Q 10-Q 0001564590-20-026394 001-39269 20898516 34 4834418 1
2020-05-20 8-K 8-K 2.02,9.01 0001564590-20-026388 001-39269 20898437 34 239429
2020-05-11 SC 13G filing.txt 0000315066-20-001492 005-91490 20862812 34 8441
2020-05-01 SC 13G oric13g2020.htm 0000935836-20-000286 005-91490 20842003 34 47690
2020-05-01 SC 13D SCHEDULE 13D 0000947871-20-000417 005-91490 20841042 34 119684
2020-04-29 SC 13G SCHEDULE 13G 0001104659-20-052583 005-91490 20826878 34 108813
2020-04-28 4 FORM 4 SUBMISSION 0001209191-20-025998 22036
2020-04-28 8-K 8-K 5.03,7.01,9.01 0001564590-20-019302 001-39269 20826255 34 1185086
2020-04-28 4 FORM 4 SUBMISSION 0001209191-20-025990 20718
2020-04-28 4 FORM 4 SUBMISSION 0001209191-20-025989 24694
2020-04-28 4 FORM 4 SUBMISSION 0001209191-20-025987 19967
2020-04-28 4 FORM 4 SUBMISSION 0001209191-20-025985 7048
2020-04-28 4 FORM 4 SUBMISSION 0001209191-20-025984 8084
2020-04-28 4 FORM 4 SUBMISSION 0001209191-20-025983 17888
2020-04-28 4 FORM 4 SUBMISSION 0001209191-20-025981 7093
2020-04-27 4 FORM 4 SUBMISSION 0001209191-20-025810 5453
2020-04-27 4 FORM 4 SUBMISSION 0001209191-20-025808 5443
2020-04-27 4 FORM 4 SUBMISSION 0001209191-20-025807 5415
2020-04-27 4 FORM 4 SUBMISSION 0001209191-20-025806 5354
2020-04-27 4 FORM 4 SUBMISSION 0001209191-20-025805 5418
2020-04-27 4 FORM 4 SUBMISSION 0001209191-20-025804 5377
2020-04-27 4 FORM 4 SUBMISSION 0001209191-20-025803 5371
2020-04-27 4 FORM 4 SUBMISSION 0001209191-20-025801 5422
2020-04-24 S-8 S-8 0001193125-20-119249 333-237840 20815984 33 76223
2020-04-24 424B4 424B4 0001193125-20-119234 333-236792 20815928 33 5701007
2020-04-23 EFFECT xslEFFECTX01/primary_doc.xml S-1,,2020-04-23 16:00:00 9999999995-20-000838 333-236792 20812380 33 1737
2020-04-23 3 FORM 3 SUBMISSION 0001209191-20-025500 11842
2020-04-23 3 FORM 3 SUBMISSION 0001209191-20-025498 10177

Latest XBRL company facts

One latest value per concept from companyfacts (215 concepts). Full history stays in the JSON.

TaxonomyTagLabelUnitValueStartEndFYFPFormFiledAccn
dei EntityCommonStockSharesOutstanding Entity Common Stock, Shares Outstanding shares 103.93M 2026-11-09 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
dei EntityPublicFloat Entity Public Float USD 862.40M 2025-06-30 2025 FY 10-K 2026-02-23 0001193125-26-064005
ecd NonPeoNeoAvgCompActuallyPaidAmt NonPeoNeoAvgCompActuallyPaidAmt USD 2.30M 2025-01-01 2025-12-31 DEF 14A 2026-04-28 0001193125-26-186911
ecd NonPeoNeoAvgTotalCompAmt NonPeoNeoAvgTotalCompAmt USD 2.26M 2025-01-01 2025-12-31 DEF 14A 2026-04-28 0001193125-26-186911
ecd PeoActuallyPaidCompAmt PeoActuallyPaidCompAmt USD 5.69M 2025-01-01 2025-12-31 DEF 14A 2026-04-28 0001193125-26-186911
ecd PeoTotalCompAmt PeoTotalCompAmt USD 5.57M 2025-01-01 2025-12-31 DEF 14A 2026-04-28 0001193125-26-186911
ecd TotalShareholderRtnAmt TotalShareholderRtnAmt USD 88.91 2025-01-01 2025-12-31 DEF 14A 2026-04-28 0001193125-26-186911
ffd NetFeeAmt NetFeeAmt USD 1,667.98 2026-07-30 S-8 2026-07-30 0001193125-26-326363
ffd TtlFeeAmt TtlFeeAmt USD 1,667.98 2026-07-30 S-8 2026-07-30 0001193125-26-326363
ffd TtlOfferingAmt TtlOfferingAmt USD 12.08M 2026-07-30 S-8 2026-07-30 0001193125-26-326363
ffd TtlOffsetAmt TtlOffsetAmt USD 0 2026-07-30 S-8 2026-07-30 0001193125-26-326363
us-gaap AccountsPayableCurrent Accounts Payable, Current USD 2.15M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap AccretionAmortizationOfDiscountsAndPremiumsInvestments Accretion (Amortization) of Discounts and Premiums, Investments USD -690,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap AccruedLiabilitiesCurrent Accrued Liabilities, Current USD 22.63M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap AccruedLiabilitiesCurrentAndNoncurrent Accrued Liabilities USD 1.90M 2021-12-31 2021 FY 10-K 2022-03-21 0000950170-22-004239
us-gaap AccruedRentCurrent Accrued Rent, Current USD 0 2021-12-31 2021 FY 10-K 2022-03-21 0000950170-22-004239
us-gaap AccruedSalariesCurrent Accrued Salaries, Current USD 7.33M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment USD 8.46M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap AccumulatedOtherComprehensiveIncomeLossNetOfTax Accumulated Other Comprehensive Income (Loss), Net of Tax USD -1.69M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap AdditionalPaidInCapitalCommonStock Additional Paid in Capital, Common Stock USD 1.16B 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD 6.19M 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD 399,000 2022-01-01 2022-12-31 2023 FY 10-K 2024-03-11 0000950170-24-029298
us-gaap AllocatedShareBasedCompensationExpense Share-based Payment Arrangement, Expense USD 20.18M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount shares 18.25M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap Assets Assets USD 366.89M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap AssetsCurrent Assets, Current USD 274.75M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax USD 3,000 2021-06-30 2021 Q2 10-Q 2021-08-10 0000950170-21-001185
us-gaap AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax USD 31,000 2020-12-31 2021 Q2 10-Q 2021-08-10 0000950170-21-001185
us-gaap AvailableForSaleDebtSecuritiesAmortizedCostBasis Debt Securities, Available-for-sale, Amortized Cost USD 90.99M 2021-06-30 2021 Q2 10-Q 2021-08-10 0000950170-21-001185
us-gaap AvailableForSaleSecuritiesDebtSecurities Debt Securities, Available-for-sale USD 90.99M 2021-06-30 2021 Q2 10-Q 2021-08-10 0000950170-21-001185
us-gaap AvailableForSaleSecuritiesDebtSecuritiesCurrent Debt Securities, Available-for-sale, Current USD 227.53M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap AvailableForSaleSecuritiesDebtSecuritiesNoncurrent Debt Securities, Available-for-sale, Noncurrent USD 83.99M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap CashAndCashEquivalentsAtCarryingValue Cash and Cash Equivalents, at Carrying Value USD 33.85M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents USD 34.34M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect USD -11.82M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Class of Warrant or Right, Exercise Price of Warrants or Rights USD/shares 0 2025-05-31 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap ClassOfWarrantOrRightOutstanding Class of Warrant or Right, Outstanding shares 4.46M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap CommonStockParOrStatedValuePerShare Common Stock, Par or Stated Value Per Share USD/shares 0 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap CommonStockSharesAuthorized Common Stock, Shares Authorized shares 1.00B 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap CommonStockSharesIssued Common Stock, Shares, Issued shares 103.87M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap CommonStockSharesOutstanding Common Stock, Shares, Outstanding shares 103.87M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap CommonStockValue Common Stock, Value, Issued USD 11,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap ComprehensiveIncomeNetOfTax Comprehensive Income (Loss), Net of Tax, Attributable to Parent USD -127.81M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap ConversionOfStockAmountConverted1 Conversion of Stock, Amount Converted USD 0 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-21 0000950170-22-004239
us-gaap ConvertiblePreferredStockSharesIssuedUponConversion Convertible Preferred Stock, Shares Issued upon Conversion shares 19.28M 2020-04-30 2021 FY 10-K 2022-03-21 0000950170-22-004239
us-gaap DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions Security 18 2020-12-31 2020 FY 10-K 2021-03-23 0001564590-21-014865
us-gaap DeferredCosts Deferred Costs, Noncurrent USD 1.34M 2019-12-31 2020 Q2 10-Q 2020-08-05 0001564590-20-036836
us-gaap DeferredOfferingCosts Deferred Offering Costs USD 2.40M 2020-03-31 2020 Q1 10-Q 2020-05-20 0001564590-20-026394
us-gaap DeferredRentCreditNoncurrent Deferred Rent Credit, Noncurrent USD 219,000 2020-12-31 2020 FY 10-K 2021-03-23 0001564590-21-014865
us-gaap DeferredTaxAssetsGoodwillAndIntangibleAssets Deferred Tax Assets, Goodwill and Intangible Assets USD 5.59M 2025-12-31 2025 FY 10-K 2026-02-23 0001193125-26-064005
us-gaap DeferredTaxAssetsGross Deferred Tax Assets, Gross USD 214.72M 2025-12-31 2025 FY 10-K 2026-02-23 0001193125-26-064005
us-gaap DeferredTaxAssetsLiabilitiesNet Deferred Tax Assets, Net USD 0 2025-12-31 2025 FY 10-K 2026-02-23 0001193125-26-064005
us-gaap DeferredTaxAssetsNet Deferred Tax Assets, Net of Valuation Allowance USD 2.11M 2025-12-31 2025 FY 10-K 2026-02-23 0001193125-26-064005
us-gaap DeferredTaxAssetsOperatingLossCarryforwards Deferred Tax Assets, Operating Loss Carryforwards USD 129.33M 2025-12-31 2025 FY 10-K 2026-02-23 0001193125-26-064005
us-gaap DeferredTaxAssetsTaxCreditCarryforwardsResearch Deferred Tax Assets, Tax Credit Carryforwards, Research USD 24.63M 2025-12-31 2025 FY 10-K 2026-02-23 0001193125-26-064005
us-gaap DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost USD 18.52M 2025-12-31 2025 FY 10-K 2026-02-23 0001193125-26-064005
us-gaap DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Deferred Rent USD 0 2021-12-31 2021 FY 10-K 2022-03-21 0000950170-22-004239
us-gaap DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Other USD 2.13M 2025-12-31 2025 FY 10-K 2026-02-23 0001193125-26-064005
us-gaap DeferredTaxAssetsValuationAllowance Deferred Tax Assets, Valuation Allowance USD 212.60M 2025-12-31 2025 FY 10-K 2026-02-23 0001193125-26-064005
us-gaap DeferredTaxLiabilities Deferred Tax Liabilities, Net USD 2.11M 2025-12-31 2025 FY 10-K 2026-02-23 0001193125-26-064005
us-gaap DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs USD 32.43M 2025-12-31 2025 FY 10-K 2026-02-23 0001193125-26-064005
us-gaap DeferredTaxLiabilitiesOther Deferred Tax Liabilities, Other USD 220,000 2025-12-31 2025 FY 10-K 2026-02-23 0001193125-26-064005
us-gaap DeferredTaxLiabilitiesPropertyPlantAndEquipment Deferred Tax Liabilities, Property, Plant and Equipment USD 29,000 2025-12-31 2025 FY 10-K 2026-02-23 0001193125-26-064005
us-gaap DefinedContributionPlanCostRecognized Defined Contribution Plan, Cost USD 900,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-23 0001193125-26-064005
us-gaap DefinedContributionPlanEmployerDiscretionaryContributionAmount Defined Contribution Plan, Employer Discretionary Contribution Amount USD 0 2020-01-01 2020-12-31 2021 FY 10-K 2022-03-21 0000950170-22-004239
us-gaap Depreciation Depreciation USD 813,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap EarningsPerShareBasic Earnings Per Share, Basic USD/shares -1.17 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap EarningsPerShareBasicAndDiluted Earnings Per Share, Basic and Diluted USD/shares -0.59 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-09 0000950170-22-008512
us-gaap EarningsPerShareDiluted Earnings Per Share, Diluted USD/shares -1.17 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap EffectiveIncomeTaxRateContinuingOperations Effective Income Tax Rate Reconciliation, Percent pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-23 0001193125-26-064005
us-gaap EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent pure 0.21 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-23 0001193125-26-064005
us-gaap EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent pure -0.235 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-23 0001193125-26-064005
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpense Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent pure -0.009 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-23 0001193125-26-064005
us-gaap EffectiveIncomeTaxRateReconciliationOtherAdjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Percent pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-23 0001193125-26-064005
us-gaap EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent pure 0.001 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-23 0001193125-26-064005
us-gaap EffectiveIncomeTaxRateReconciliationTaxCreditsResearch Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent pure 0.04 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-23 0001193125-26-064005
us-gaap EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount USD 36.40M 2021-12-31 2021 FY 10-K 2022-03-21 0000950170-22-004239
us-gaap ExchangeFees Exchange Fees USD 0 2024-07-08 2024 FY 10-K 2025-02-18 0000950170-25-022273
us-gaap FairValueAssetsLevel1ToLevel2TransfersAmount Fair Value, Assets, Level 1 to Level 2 Transfers, Amount USD 0 2022-03-31 2022 Q1 10-Q 2022-05-09 0000950170-22-008512
us-gaap FairValueAssetsLevel2ToLevel1TransfersAmount Fair Value, Assets, Level 2 to Level 1 Transfers, Amount USD 0 2022-03-31 2022 Q1 10-Q 2022-05-09 0000950170-22-008512
us-gaap GainLossOnDispositionOfAssets1 Gain (Loss) on Disposition of Assets USD 0 2024-01-01 2024-12-31 2024 FY 10-K 2025-02-18 0000950170-25-022273
us-gaap GeneralAndAdministrativeExpense General and Administrative Expense USD 25.38M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap IncomeTaxExaminationPenaltiesAndInterestAccrued Income Tax Examination, Penalties and Interest Accrued USD 0 2025-12-31 2025 FY 10-K 2026-02-23 0001193125-26-064005
us-gaap IncomeTaxExpenseBenefit Income Tax Expense (Benefit) USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-23 0001193125-26-064005
us-gaap IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount USD 30.43M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-23 0001193125-26-064005
us-gaap IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount USD -27.19M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-23 0001193125-26-064005
us-gaap IncomeTaxReconciliationNondeductibleExpense Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount USD 1.19M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-23 0001193125-26-064005
us-gaap IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount USD 766,000 2024-01-01 2024-12-31 2025 FY 10-K 2026-02-23 0001193125-26-064005
us-gaap IncomeTaxReconciliationOtherAdjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Amount USD -17,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-23 0001193125-26-064005
us-gaap IncomeTaxReconciliationOtherReconcilingItems Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount USD 132,000 2024-01-01 2024-12-31 2025 FY 10-K 2026-02-23 0001193125-26-064005
us-gaap IncomeTaxReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount USD -186,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-23 0001193125-26-064005
us-gaap IncomeTaxReconciliationTaxCreditsResearch Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount USD 5.20M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-23 0001193125-26-064005
us-gaap IncreaseDecreaseInAccountsPayableAndAccruedLiabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities USD 2.11M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Increase (Decrease) in Prepaid Expense and Other Assets USD 4.49M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap InterestIncomeExpenseNonoperatingNet Interest Income (Expense), Nonoperating, Net USD 1.73M 2023-01-01 2023-03-31 2023 Q1 10-Q 2023-05-08 0000950170-23-018839
us-gaap InterestIncomeOther Interest Income, Other USD 0 2022-01-01 2022-09-30 2022 Q3 10-Q 2022-11-07 0000950170-22-022631
us-gaap LesseeOperatingLeaseLiabilityPaymentsDue Lessee, Operating Lease, Liability, to be Paid USD 8.14M 2025-12-31 2025 FY 10-K 2026-02-23 0001193125-26-064005
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive Lessee, Operating Lease, Liability, to be Paid, after Year Five USD 0 2025-12-31 2025 FY 10-K 2026-02-23 0001193125-26-064005
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Lessee, Operating Lease, Liability, to be Paid, Year One USD 3.46M 2025-12-31 2025 FY 10-K 2026-02-23 0001193125-26-064005
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFive Lessee, Operating Lease, Liability, to be Paid, Year Five USD 0 2025-12-31 2025 FY 10-K 2026-02-23 0001193125-26-064005
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFour Lessee, Operating Lease, Liability, to be Paid, Year Four USD 0 2025-12-31 2025 FY 10-K 2026-02-23 0001193125-26-064005
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearThree Lessee, Operating Lease, Liability, to be Paid, Year Three USD 1.18M 2025-12-31 2025 FY 10-K 2026-02-23 0001193125-26-064005
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Lessee, Operating Lease, Liability, to be Paid, Year Two USD 3.50M 2025-12-31 2025 FY 10-K 2026-02-23 0001193125-26-064005
us-gaap LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year USD 492,000 2021-09-30 2021 Q3 10-Q 2021-11-08 0000950170-21-003477
us-gaap LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Lessee, Operating Lease, Liability, Undiscounted Excess Amount USD 699,000 2025-12-31 2025 FY 10-K 2026-02-23 0001193125-26-064005
us-gaap Liabilities Liabilities USD 27.38M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap LiabilitiesAndStockholdersEquity Liabilities and Equity USD 366.89M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap LiabilitiesCurrent Liabilities, Current USD 24.78M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap LongTermDebt Long-term Debt USD 10.50M 2021-12-31 2021 FY 10-K 2022-03-21 0000950170-22-004239
us-gaap MarketableSecurities Marketable Securities USD 0 2019-12-31 2020 Q3 10-Q 2020-11-05 0001564590-20-051363
us-gaap MarketableSecuritiesCurrent Marketable Securities, Current USD 90.99M 2021-06-30 2021 Q2 10-Q 2021-08-10 0000950170-21-001185
us-gaap NetCashProvidedByUsedInFinancingActivities Net Cash Provided by (Used in) Financing Activities USD 62.77M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap NetCashProvidedByUsedInInvestingActivities Net Cash Provided by (Used in) Investing Activities USD 31.43M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap NetCashProvidedByUsedInOperatingActivities Net Cash Provided by (Used in) Operating Activities USD -106.03M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap NetIncomeLoss Net Income (Loss) Attributable to Parent USD -125.33M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1 Noncash or Part Noncash Acquisition, Fixed Assets Acquired USD 436,000 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-21 0000950170-22-004239
us-gaap NonoperatingIncomeExpense Nonoperating Income (Expense) USD 11.13M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap NumberOfOperatingSegments Number of Operating Segments Segments 1 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap OperatingExpenses Operating Expenses USD 136.47M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap OperatingIncomeLoss Operating Income (Loss) USD -136.47M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap OperatingLeaseCost Operating Lease, Cost USD 3.11M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-23 0001193125-26-064005
us-gaap OperatingLeaseExpense Operating Lease, Expense USD 1.40M 2020-01-01 2020-12-31 2021 FY 10-K 2022-03-21 0000950170-22-004239
us-gaap OperatingLeaseLiability Operating Lease, Liability USD 7.44M 2025-12-31 2025 FY 10-K 2026-02-23 0001193125-26-064005
us-gaap OperatingLeaseLiabilityCurrent Operating Lease, Liability, Current USD 3.35M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap OperatingLeaseLiabilityNoncurrent Operating Lease, Liability, Noncurrent USD 4.11M 2025-12-31 2025 FY 10-K 2026-02-23 0001193125-26-064005
us-gaap OperatingLeasePayments Operating Lease, Payments USD 3.31M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-23 0001193125-26-064005
us-gaap OperatingLeaseRightOfUseAsset Operating Lease, Right-of-Use Asset USD 6.66M 2025-12-31 2025 FY 10-K 2026-02-23 0001193125-26-064005
us-gaap OperatingLeasesFutureMinimumPaymentsDue Operating Leases, Future Minimum Payments Due USD 2.63M 2021-12-31 2021 FY 10-K 2022-03-21 0000950170-22-004239
us-gaap OperatingLeasesFutureMinimumPaymentsDueCurrent Operating Leases, Future Minimum Payments Due, Next Twelve Months USD 1.94M 2021-12-31 2021 FY 10-K 2022-03-21 0000950170-22-004239
us-gaap OperatingLeasesFutureMinimumPaymentsDueInFourYears Operating Leases, Future Minimum Payments, Due in Four Years USD 0 2020-12-31 2020 FY 10-K 2021-03-23 0001564590-21-014865
us-gaap OperatingLeasesFutureMinimumPaymentsDueInThreeYears Operating Leases, Future Minimum Payments, Due in Three Years USD 0 2020-12-31 2020 FY 10-K 2021-03-23 0001564590-21-014865
us-gaap OperatingLeasesFutureMinimumPaymentsDueInTwoYears Operating Leases, Future Minimum Payments, Due in Two Years USD 686,000 2021-12-31 2021 FY 10-K 2022-03-21 0000950170-22-004239
us-gaap OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear Operating Leases, Future Minimum Payments, Remainder of Fiscal Year USD 478,000 2020-09-30 2020 Q3 10-Q 2020-11-05 0001564590-20-051363
us-gaap OperatingLeaseWeightedAverageDiscountRatePercent Operating Lease, Weighted Average Discount Rate, Percent pure 0.084 2025-12-31 2025 FY 10-K 2026-02-23 0001193125-26-064005
us-gaap OperatingLossCarryforwards Operating Loss Carryforwards USD 424.30M 2025-12-31 2025 FY 10-K 2026-02-23 0001193125-26-064005
us-gaap OtherAccruedLiabilitiesCurrent Other Accrued Liabilities, Current USD 1.76M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap OtherAssetsNoncurrent Other Assets, Noncurrent USD 6.06M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap OtherComprehensiveIncomeLossNetOfTax Other Comprehensive Income (Loss), Net of Tax USD -31,000 2020-01-01 2020-12-31 2020 FY 10-K 2021-03-23 0001564590-21-014865
us-gaap OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax USD -2.48M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap OtherLiabilitiesNoncurrent Other Liabilities, Noncurrent USD 2.61M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap OtherNonoperatingIncome Other Nonoperating Income USD 0 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-16 0000950170-23-008483
us-gaap PaymentsOfFinancingCosts Payments of Financing Costs USD 1.64M 2020-01-01 2020-03-31 2021 Q1 10-Q 2021-05-06 0001564590-21-024997
us-gaap PaymentsOfStockIssuanceCosts Payments of Stock Issuance Costs USD 993,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap PaymentsToAcquireInvestments Payments to Acquire Investments USD 143.10M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap PaymentsToAcquireMarketableSecurities Payments to Acquire Marketable Securities USD 124.64M 2020-01-01 2020-09-30 2020 Q3 10-Q 2020-11-05 0001564590-20-051363
us-gaap PaymentsToAcquirePropertyPlantAndEquipment Payments to Acquire Property, Plant, and Equipment USD 465,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap PreferredStockParOrStatedValuePerShare Preferred Stock, Par or Stated Value Per Share USD/shares 0 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap PreferredStockSharesAuthorized Preferred Stock, Shares Authorized shares 200.00M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap PreferredStockSharesIssued Preferred Stock, Shares Issued shares 0 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap PreferredStockSharesOutstanding Preferred Stock, Shares Outstanding shares 0 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap PreferredStockValue Preferred Stock, Value, Issued USD 0 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap PrepaidExpenseAndOtherAssetsCurrent Prepaid Expense and Other Assets, Current USD 13.38M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap ProceedsFromIssuanceInitialPublicOffering Proceeds from Issuance Initial Public Offering USD 138.00M 2020-01-01 2020-12-31 2020 FY 10-K 2021-03-23 0001564590-21-014865
us-gaap ProceedsFromIssuanceOfCommonStock Proceeds from Issuance of Common Stock USD 60.88M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap ProceedsFromIssuanceOfPreferredStockAndPreferenceStock Proceeds from Issuance of Preferred Stock and Preference Stock USD 354,000 2022-01-01 2022-09-30 2022 Q3 10-Q 2022-11-07 0000950170-22-022631
us-gaap ProceedsFromIssuanceOfPrivatePlacement Proceeds from Issuance of Private Placement USD 125.00M 2025-05-23 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap ProceedsFromSaleAndMaturityOfMarketableSecurities Proceeds from Sale and Maturity of Marketable Securities USD 175.00M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap ProceedsFromSaleOfNotesReceivable Proceeds from Sale of Notes Receivable USD 0 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-21 0000950170-22-004239
us-gaap ProceedsFromStockOptionsExercised Proceeds from Stock Options Exercised USD 2.21M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap ProfitLoss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest USD -48.08M 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap PropertyPlantAndEquipmentGross Property, Plant and Equipment, Gross USD 10.55M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap PropertyPlantAndEquipmentNet Property, Plant and Equipment, Net USD 2.08M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap ResearchAndDevelopmentExpense Research and Development Expense USD 14.98M 2020-01-01 2020-06-30 2020 Q2 10-Q 2020-08-05 0001564590-20-036836
us-gaap ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost Research and Development Expense (Excluding Acquired in Process Cost) USD 111.09M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap ResearchAndDevelopmentInProcess Research and Development in Process USD 5.00M 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-16 0000950170-23-008483
us-gaap RestrictedCashAndCashEquivalents Restricted Cash and Cash Equivalents USD 491,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap RetainedEarningsAccumulatedDeficit Retained Earnings (Accumulated Deficit) USD -817.58M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap SaleOfStockConsiderationReceivedOnTransaction Sale of Stock, Consideration Received on Transaction USD 124.40M 2025-05-23 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap ShareBasedCompensation Share-based Payment Arrangement, Noncash Expense USD 20.18M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate pure 0 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-21 0000950170-22-004239
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate pure 1.005 2019-01-01 2019-06-30 2020 Q2 10-Q 2020-08-05 0001564590-20-036836
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum pure 0.884 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-21 0000950170-22-004239
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum pure 0.823 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-21 0000950170-22-004239
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate pure 0.026 2019-01-01 2019-06-30 2020 Q2 10-Q 2020-08-05 0001564590-20-036836
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum pure 0.013 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-21 0000950170-22-004239
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum pure 0.006 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-21 0000950170-22-004239
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value USD 80.48M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number shares 10.49M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price USD/shares 5.94 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value USD 2.30M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-23 0001193125-26-064005
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period shares 186,928 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price USD/shares 8.65 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross shares 3.90M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value USD/shares 6.22 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-23 0001193125-26-064005
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value USD 112.49M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number shares 17.14M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price USD/shares 6.99 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price USD/shares 4.67 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price USD/shares 8.6 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap SharePrice Share Price USD/shares 1.6 2018-12-31 2020 FY 10-K 2021-03-23 0001564590-21-014865
us-gaap SharesIssuedPricePerShare Shares Issued, Price Per Share USD/shares 6.5 2025-05-23 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap StockholdersEquity Stockholders' Equity Attributable to Parent USD 339.50M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap StockholdersEquityNoteStockSplitConversionRatio1 Stockholders' Equity Note, Stock Split, Conversion Ratio pure 0.25 2020-04-28 2021 FY 10-K 2022-03-21 0000950170-22-004239
us-gaap StockIssuedDuringPeriodSharesNewIssues Stock Issued During Period, Shares, New Issues shares 14.13M 2025-05-01 2025-05-31 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap StockIssuedDuringPeriodSharesStockOptionsExercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period shares 473,113 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap StockIssuedDuringPeriodValueAcquisitions Stock Issued During Period, Value, Acquisitions USD 19.84M 2020-01-01 2020-12-31 2021 FY 10-K 2022-03-21 0000950170-22-004239
us-gaap StockIssuedDuringPeriodValueConversionOfConvertibleSecurities Stock Issued During Period, Value, Conversion of Convertible Securities USD 178.06M 2020-01-01 2020-12-31 2021 FY 10-K 2022-03-21 0000950170-22-004239
us-gaap StockIssuedDuringPeriodValueEmployeeStockPurchasePlan Stock Issued During Period, Value, Employee Stock Purchase Plan USD 679,000 2026-04-01 2026-06-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap StockIssuedDuringPeriodValueNewIssues Stock Issued During Period, Value, New Issues USD 59.89M 2026-01-01 2026-03-31 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap StockIssuedDuringPeriodValueStockOptionsExercised Stock Issued During Period, Value, Stock Options Exercised USD 806,000 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit Tax Cuts and Jobs Act, Measurement Period Adjustment, Income Tax Expense (Benefit) USD 0 2020-01-01 2020-12-31 2020 FY 10-K 2021-03-23 0001564590-21-014865
us-gaap TemporaryEquityCarryingAmountAttributableToParent Temporary Equity, Carrying Amount, Attributable to Parent USD 178.06M 2019-12-31 2020 FY 10-K 2021-03-23 0001564590-21-014865
us-gaap TemporaryEquityLiquidationPreference Temporary Equity, Liquidation Preference USD 0 2020-12-31 2020 FY 10-K 2021-03-23 0001564590-21-014865
us-gaap TemporaryEquityParOrStatedValuePerShare Temporary Equity, Par or Stated Value Per Share USD/shares 0 2020-12-31 2020 FY 10-K 2021-03-23 0001564590-21-014865
us-gaap TemporaryEquitySharesAuthorized Temporary Equity, Shares Authorized shares 20.35M 2019-12-31 2021 FY 10-K 2022-03-21 0000950170-22-004239
us-gaap TemporaryEquitySharesIssued Temporary Equity, Shares Issued shares 19.28M 2019-12-31 2021 FY 10-K 2022-03-21 0000950170-22-004239
us-gaap TemporaryEquitySharesOutstanding Temporary Equity, Shares Outstanding shares 0 2020-04-30 2021 FY 10-K 2022-03-21 0000950170-22-004239
us-gaap UnrecognizedTaxBenefits Unrecognized Tax Benefits USD 4.77M 2025-12-31 2025 FY 10-K 2026-02-23 0001193125-26-064005
us-gaap UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-23 0001193125-26-064005
us-gaap UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions USD 1.04M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-23 0001193125-26-064005
us-gaap UnrecognizedTaxBenefitsPeriodIncreaseDecrease Unrecognized Tax Benefits, Period Increase (Decrease) USD 965,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-23 0001193125-26-064005
us-gaap ValuationAllowanceDeferredTaxAssetChangeInAmount Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount USD 40.00M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-23 0001193125-26-064005
us-gaap WeightedAverageNumberOfDilutedSharesOutstanding Weighted Average Number of Shares Outstanding, Diluted shares 107.23M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577
us-gaap WeightedAverageNumberOfShareOutstandingBasicAndDiluted Weighted Average Number of Shares Outstanding, Basic and Diluted shares 39.43M 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-09 0000950170-22-008512
us-gaap WeightedAverageNumberOfSharesOutstandingBasic Weighted Average Number of Shares Outstanding, Basic shares 107.23M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463577

Financialist News Desk

Our desk turns official SEC filings into news. Each story is checked against the original filing. About us → · Editorial standards →